The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 11, Issue 1, 2009, Pages 41-44

  Krones, R ^a   Schutte C ^a   Heise, Tim ^a,b  

^a St Franziskus Hospital Koln   (Germany)

^b PROFIL Institut für Stoffwechselforschung   (Germany)

Author keywords

Elderly patients; Insulin aspart; Pharmacodynamics; Pharmacokinetics; Type 2 diabetes

Indexed keywords

INSULIN; INSULIN ASPART;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EATING HABIT; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE;

EID: 58149204235     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00988.x     Document Type: Article

References (16)

1. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T. No increase in the duration of action with rising doses of insulin aspart (Abstract 551-P). Diabetes 2003; 52(Suppl. 1): A128.
2. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: Human insulin B28Asp. Diabet Med 1993a; 10: 535-539.
3. Brunner GA, Hirschberger S, Sendlhofer G et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000; 17: 371-375.
4. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diabetes Care 1998; 21: 570-573.
5. Milicevic Z, Profozic V, Wyatt J et al. Intramuscular injection of insulin lispro or soluble human insulin: Pharmacokinetics and glucodynamics in type 2 diabetes. Diabet Med 2001; 18: 562-566.
6. Sargin H, Sargin M, Altuntas Y et al. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes. Diabetes Res Clin Pract 2003; 62: 79-86.
7. Rosenfalck AM, Thorsby P, Kjems L et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000; 37: 41-46.
8. Turnheim K. When drug therapy gets old: Pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38: 843-853.
9. Stepka M, Rogala H, Czyzyk A. Hypoglycemia: A major problem in the management of diabetes in the elderly. Aging (Milano) 1993; 5: 117-121.
10. Berger M, Mühlhauser I. Diabetes care and patient-oriented outcomes. JAMA 1999; 281: 1676-1678.
11. Heinemann L, Kapitza C, Starke AAR, Heise T. Time-action profile of the insulin analogue B28Asp. Diabet Med 1996a; 13: 683-684.
12. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22: 801-805.
13. Heinemann L, Heise T, Wahl LC et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: Using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996b; 13: 625-629.
14. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 2100-2105.
15. Heinemann L, Heise T, Ampudia J, Starke AAR. Action profiles of rapid-acting human insulin analogues. In: Berger M, Gries FA eds. Frontiers in Insulin Pharmacology. Stuttgart and New York: Georg Thieme Verlag, 1993b; 87-96.
16. Heller SR, Colagiuri S, Vaaler S et al. Hypoglycaemia with insulin aspart: A double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med 2004; 21: 769-775.